Trial Profile
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms REACTION
- 11 Jan 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 11 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Jun 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2023.